Elite Pharmaceuticals（ELTP）株式概要スペシャリティファーマであるエリート・ファーマシューティカルズ・インクは、経口剤、放出制御製剤、ジェネリック医薬品の開発、製造、販売に従事している。 詳細ELTP ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績3/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より86.5%で取引されている 今年は黒字化を達成 リスク分析高いレベルの非現金収入 すべてのリスクチェックを見るELTP Community Fair Values Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.3568.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-42m652m2016201920222025202620282031Revenue US$651.6mEarnings US$201.9mAdvancedSet Fair ValueView all narrativesElite Pharmaceuticals, Inc. 競合他社Zevra TherapeuticsSymbol: NasdaqGS:ZVRAMarket cap: US$592.9mSIGA TechnologiesSymbol: NasdaqGM:SIGAMarket cap: US$335.7mTheravance BiopharmaSymbol: NasdaqGM:TBPHMarket cap: US$843.9mXeris Biopharma HoldingsSymbol: NasdaqGS:XERSMarket cap: US$1.1b価格と性能株価の高値、安値、推移の概要Elite Pharmaceuticals過去の株価現在の株価US$0.3552週高値US$0.8252週安値US$0.33ベータ0.381ヶ月の変化-4.85%3ヶ月変化-14.42%1年変化-35.07%3年間の変化887.14%5年間の変化507.74%IPOからの変化-82.73%最新ニュースお知らせ • Feb 12Elite Pharmaceuticals, Inc. to Report Q3, 2026 Results on Feb 17, 2026Elite Pharmaceuticals, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026お知らせ • Nov 10Elite Pharmaceuticals, Inc. to Report Q2, 2026 Results on Nov 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Aug 09Elite Pharmaceuticals, Inc. to Report Q1, 2026 Results on Aug 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q1, 2026 results on Aug 14, 2025お知らせ • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2025 Results on Jun 30, 2025Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2025 results on Jun 30, 2025お知らせ • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2025 Results on Nov 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024お知らせ • Jun 27Elite Pharmaceuticals, Inc. to Report Q4, 2024 Results on Jul 01, 2024Elite Pharmaceuticals, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Jul 01, 2024最新情報をもっと見るRecent updatesお知らせ • Feb 12Elite Pharmaceuticals, Inc. to Report Q3, 2026 Results on Feb 17, 2026Elite Pharmaceuticals, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026お知らせ • Nov 10Elite Pharmaceuticals, Inc. to Report Q2, 2026 Results on Nov 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Aug 09Elite Pharmaceuticals, Inc. to Report Q1, 2026 Results on Aug 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q1, 2026 results on Aug 14, 2025お知らせ • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2025 Results on Jun 30, 2025Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2025 results on Jun 30, 2025お知らせ • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2025 Results on Nov 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024お知らせ • Jun 27Elite Pharmaceuticals, Inc. to Report Q4, 2024 Results on Jul 01, 2024Elite Pharmaceuticals, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Jul 01, 2024お知らせ • May 23Elite Pharmaceuticals Receives Fda Approval for Generic MethotrexateElite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label. IQVIA reported annual sales of $64.3 million for the twelve months ending March 2024 for the generic market for this product.お知らせ • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2024 Results on Feb 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q3, 2024 results on Feb 14, 2024お知らせ • Dec 26Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System StimulantElite Pharmaceuticals, Inc. announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.お知らせ • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2024 Results on Nov 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2023お知らせ • Sep 26Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic ProductElite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.お知らせ • Sep 08Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr. Ward previously served as the Company's Chief Financial Officer from July 2009 through May 2021, and the Company is pleased to have Mr. Ward join the company again as CFO. Mr. Ward has over 30 years of industry experience, most recently as chief financial officer of Mirror Biologics, Inc., a privately held life science company and before that as chief financial officer of Enveric Biosciences, Inc., a publicly traded biotech company. Prior to Mr. Ward's initial tenure with the Company, Mr. Ward filled multiple finance and supply chain leadership roles with the Actavis Group and its U.S. subsidiary, Amide Pharmaceutical, Inc. and was also a consultant for Centennial Communications Corp., a Nasdaq-listed wireless communications provider where he was engaged in improving internal controls and supporting Sarbanes-Oxley compliance. Mr. Ward began his career as a certified public accountant in the audit department of KPMG and holds a Bachelor of Science degree in accounting from Long Island University in Brooklyn, N.Y, graduating summa cum laude.お知らせ • Aug 29Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. engaged in the development, manufacture, and distribution of niche generic products, reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product. The studies were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two sequence, two-way crossover comparative bioavailability studies in healthy, adult, human subjects under fed and fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.お知らせ • Aug 10Elite Pharmaceuticals, Inc. to Report Q1, 2024 Results on Aug 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q1, 2024 results on Aug 14, 2023お知らせ • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Jun 29, 2023Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Jun 29, 2023お知らせ • May 04Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegrino joins Elite with more than 30 years of experience in financial and operational leadership, primarily in the life sciences sector, including manufacturing and distribution. Pellegrino served for nearly a decade as Senior Director of Finance and Administration at Kedrion Biopharma, Inc., the U.S. division of a multi-national company. Pellegrino also served as CFO for Digital Products, Inc. and spent fifteen years as Vice President of Finance for Romaco, Inc. He most recently held a position at Barbera & Barbera as a consultant in finance and tax. Pellegrino brings a wealth of diversified leadership in corporate operations, corporate finance, and accounting for private and public companies.お知らせ • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2023 Results on Feb 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 14, 2023お知らせ • Feb 08Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product. The studies were open label, single-dose crossover comparative bioavailability studies in volunteers of male and female patients who were already on established drug regimens under fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.お知らせ • Nov 09Elite Pharmaceuticals, Inc. to Report Q2, 2023 Results on Nov 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q2, 2023 results on Nov 14, 2022お知らせ • Sep 08Elite Pharmaceuticals, Inc. Appoints Kirko Kirkov as Chief Commercial OfficerOn September 5, 2022, Elite Pharmaceuticals, Inc. entered into an employment agreement with Kirko Kirkov to serve as the Registrants’ Chief Commercial Officer effective September 6, 2022. Mr. Kirkov joins Elite as an accomplished and multi-faceted leader with more than twenty years of in-depth business development skills across international pharmaceutical organizations. Before joining the Registrant, Mr. Kirkov served as General Manager of Vertice Pharma, a specialty generics pharmaceutical company, from February 2020 to present. From April 2008 to February 2020, Mr. Kirkov was employed by Sandoz and served in positions of increasing responsibilities beginning with Country Head & Managing Director of Bulgaria from 2008 to 2011. From 2011 to 2013, Mr. Kirkov served as Sandoz’s Business Unit Head, Branded Prescription Generics in Russia, and most recently, from January 2013 to February 2020, served as Sandoz’s Executive Director, Commercial Operations. Mr. Kirkov brings with him a broad range of experience in the areas of business development, operationalization of commercial strategy, and implementation of retail and wholesale channel sales operations, having overseen sales portfolios consisting of 400+ product families, and 1500+ SKUs covering both generic and branded products. Mr. Kirkov has a Bachelor of Science in Mechanical Engineering /Engineering Management from the University of Ottawa, two Masters of Science degrees respectively in Naval Architecture and Ocean Systems Management from the Massachusetts Institute of Technology, a Masters of Science in Applied Positive Psychology and Coaching from the University of East London, and an MBA from the University of Durham. Mr. Kirkov joins Elite in a newly created position to oversee the sale and marketing of commercial products not under license under Elite’s label.お知らせ • Aug 12Elite Pharmaceuticals, Inc. to Report Q1, 2023 Results on Aug 15, 2022Elite Pharmaceuticals, Inc. announced that they will report Q1, 2023 results on Aug 15, 2022お知らせ • Jun 24Elite Pharmaceuticals, Inc. to Report Fiscal Year 2022 Results on Jun 29, 2022Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2022 results on Jun 29, 2022お知らせ • May 12Elite Pharmaceuticals, Inc. Announces the Appointment of Robert Chen, CPA/MPA, as Chief Financial Officer, Effective May 16, 2022, Succeeding Marc BregmanElite Pharmaceuticals, Inc. announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer, effective May 16, 2022, succeeding Marc Bregman. Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and public, ranging from preclinical development to commercial operations. Mr. Chen brings with him extensive and diversified financial leadership background in the areas of financial reporting, including manufacturing, financial and cost accounting, SEC, GAAP and IFRS, as well as financial planning and analysis. Mr. Chen previously served in roles as CFO, Vice President of Finance, and Corporate Controller primarily in the life sciences sector. Mr. Chen most recently served as Vice President of Finance for KBP Biosciences, a clinical-stage biotech start-up. Mr. Chen also held financial positions with Bradley Pharmaceuticals, Novartis, Victory Commercial Management, Medimetriks Pharmaceuticals, and Taiho Oncology.お知らせ • Apr 19+ 1 more updateMarc Bregman Notifies Elite Pharmaceuticals, Inc. of His Intent to Leave and Resign from His Position as Chief Financial Officer, Treasurer and SecretaryOn April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc. of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary to pursue another opportunity. Mr. Bregman's last day with the Company will be April 29, 2022.お知らせ • Feb 10Elite Pharmaceuticals, Inc. to Report Q3, 2022 Results on Feb 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q3, 2022 results on Feb 14, 2022お知らせ • Feb 11Elite Pharmaceuticals, Inc. to Report Q3, 2021 Results on Feb 16, 2021Elite Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Feb 16, 2021お知らせ • Nov 12Elite Pharmaceuticals, Inc. to Report Q2, 2021 Results on Nov 16, 2020Elite Pharmaceuticals, Inc. announced that they will report Q2, 2021 results at 8:40 PM, GMT Standard Time on Nov 16, 2020お知らせ • Aug 13Elite Pharmaceuticals, Inc. to Report Q1, 2021 Results on Aug 14, 2020Elite Pharmaceuticals, Inc. announced that they will report Q1, 2021 results at 8:40 PM, GMT Standard Time on Aug 14, 2020株主還元ELTPUS PharmaceuticalsUS 市場7D0.1%5.4%1.2%1Y-35.1%44.3%28.7%株主還元を見る業界別リターン: ELTP過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: ELTPは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is ELTP's price volatile compared to industry and market?ELTP volatilityELTP Average Weekly Movement4.2%Pharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: ELTP 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ELTPの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199768Nasrat Hakimwww.elitepharma.comスペシャリティファーマであるエリート・ファーマシューティカルズ・インクは、経口剤、放出制御製剤、ジェネリック医薬品の開発、製造、販売に従事している。同社は、ジェネリック医薬品の簡略新薬申請とブランド医薬品の新薬申請セグメントを通じて事業を展開している。Adipex-Pブランドの肥満症治療薬Phentermine HCl 37.5mg錠剤、15mgおよび30mgカプセル、Bontrilブランドの肥満症治療薬Phendimetrazine Tartrate 35mg錠剤、Reviaブランドの疼痛治療薬Naltrexone HCl 50mg錠剤、循環器疾患治療薬Isradipine 2.5mgおよび5mgカプセルなど、さまざまなジェネリック医薬品および経口投与医薬品を所有、ライセンス供与、製造、販売している。また、「Surmontil」ブランドでトリミプラミンマレイン酸塩即時放出抗うつ薬カプセル、「Adderall」ブランドでデキストロアンフェタミンサッカレート、アンフェタミンアスパラギン酸塩、デキストロアンフェタミン硫酸塩、アンフェタミン硫酸塩即時放出錠、「Adderall XR」ブランドでデキストロアンフェタミンサッカレート、アンフェタミンアスパラギン酸塩、デキストロアンフェタミン硫酸塩、アンフェタミン硫酸塩徐放カプセルなどを中枢神経疾患向けに提供している；Dantriumブランドの筋弛緩薬Dantrolene Sodiumカプセル、Naltrexone配合の即時放出型オキシコドンSequestOX、Loxapineブランドの抗精神病薬Loxapine Succinateカプセル、軽度から中等度の疼痛治療薬Acetaminophen and Codeine Phosphate、抗生物質製品。さらに、疼痛、アレルギー、肥満症、注意欠陥、感染症などの分野で、サードパーティからの受託ベースで放出制御型製品を製造している。さらに、乱用抑止オピオイド製品の開発も行っている。エリート・ファーマシューティカルズ・インクは1997年に設立され、ニュージャージー州ノースベールに本社を置いている。もっと見るElite Pharmaceuticals, Inc. 基礎のまとめElite Pharmaceuticals の収益と売上を時価総額と比較するとどうか。ELTP 基礎統計学時価総額US$372.12m収益（TTM）US$43.41m売上高(TTM)US$140.12m8.6xPER（株価収益率2.7xP/SレシオELTP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ELTP 損益計算書（TTM）収益US$140.12m売上原価US$68.57m売上総利益US$71.55mその他の費用US$28.14m収益US$43.41m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.04グロス・マージン51.06%純利益率30.98%有利子負債／自己資本比率3.8%ELTP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 06:26終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Elite Pharmaceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 12Elite Pharmaceuticals, Inc. to Report Q3, 2026 Results on Feb 17, 2026Elite Pharmaceuticals, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026
お知らせ • Nov 10Elite Pharmaceuticals, Inc. to Report Q2, 2026 Results on Nov 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Aug 09Elite Pharmaceuticals, Inc. to Report Q1, 2026 Results on Aug 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q1, 2026 results on Aug 14, 2025
お知らせ • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2025 Results on Jun 30, 2025Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2025 results on Jun 30, 2025
お知らせ • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2025 Results on Nov 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024
お知らせ • Jun 27Elite Pharmaceuticals, Inc. to Report Q4, 2024 Results on Jul 01, 2024Elite Pharmaceuticals, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Jul 01, 2024
お知らせ • Feb 12Elite Pharmaceuticals, Inc. to Report Q3, 2026 Results on Feb 17, 2026Elite Pharmaceuticals, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026
お知らせ • Nov 10Elite Pharmaceuticals, Inc. to Report Q2, 2026 Results on Nov 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Aug 09Elite Pharmaceuticals, Inc. to Report Q1, 2026 Results on Aug 14, 2025Elite Pharmaceuticals, Inc. announced that they will report Q1, 2026 results on Aug 14, 2025
お知らせ • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2025 Results on Jun 30, 2025Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2025 results on Jun 30, 2025
お知らせ • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2025 Results on Nov 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024
お知らせ • Jun 27Elite Pharmaceuticals, Inc. to Report Q4, 2024 Results on Jul 01, 2024Elite Pharmaceuticals, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Jul 01, 2024
お知らせ • May 23Elite Pharmaceuticals Receives Fda Approval for Generic MethotrexateElite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label. IQVIA reported annual sales of $64.3 million for the twelve months ending March 2024 for the generic market for this product.
お知らせ • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2024 Results on Feb 14, 2024Elite Pharmaceuticals, Inc. announced that they will report Q3, 2024 results on Feb 14, 2024
お知らせ • Dec 26Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System StimulantElite Pharmaceuticals, Inc. announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.
お知らせ • Nov 11Elite Pharmaceuticals, Inc. to Report Q2, 2024 Results on Nov 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2023
お知らせ • Sep 26Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic ProductElite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.
お知らせ • Sep 08Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr. Ward previously served as the Company's Chief Financial Officer from July 2009 through May 2021, and the Company is pleased to have Mr. Ward join the company again as CFO. Mr. Ward has over 30 years of industry experience, most recently as chief financial officer of Mirror Biologics, Inc., a privately held life science company and before that as chief financial officer of Enveric Biosciences, Inc., a publicly traded biotech company. Prior to Mr. Ward's initial tenure with the Company, Mr. Ward filled multiple finance and supply chain leadership roles with the Actavis Group and its U.S. subsidiary, Amide Pharmaceutical, Inc. and was also a consultant for Centennial Communications Corp., a Nasdaq-listed wireless communications provider where he was engaged in improving internal controls and supporting Sarbanes-Oxley compliance. Mr. Ward began his career as a certified public accountant in the audit department of KPMG and holds a Bachelor of Science degree in accounting from Long Island University in Brooklyn, N.Y, graduating summa cum laude.
お知らせ • Aug 29Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. engaged in the development, manufacture, and distribution of niche generic products, reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product. The studies were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two sequence, two-way crossover comparative bioavailability studies in healthy, adult, human subjects under fed and fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.
お知らせ • Aug 10Elite Pharmaceuticals, Inc. to Report Q1, 2024 Results on Aug 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q1, 2024 results on Aug 14, 2023
お知らせ • Jun 23Elite Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Jun 29, 2023Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Jun 29, 2023
お知らせ • May 04Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial OfficerElite Pharmaceuticals, Inc. announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegrino joins Elite with more than 30 years of experience in financial and operational leadership, primarily in the life sciences sector, including manufacturing and distribution. Pellegrino served for nearly a decade as Senior Director of Finance and Administration at Kedrion Biopharma, Inc., the U.S. division of a multi-national company. Pellegrino also served as CFO for Digital Products, Inc. and spent fifteen years as Vice President of Finance for Romaco, Inc. He most recently held a position at Barbera & Barbera as a consultant in finance and tax. Pellegrino brings a wealth of diversified leadership in corporate operations, corporate finance, and accounting for private and public companies.
お知らせ • Feb 09Elite Pharmaceuticals, Inc. to Report Q3, 2023 Results on Feb 14, 2023Elite Pharmaceuticals, Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 14, 2023
お知らせ • Feb 08Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc. reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product. The studies were open label, single-dose crossover comparative bioavailability studies in volunteers of male and female patients who were already on established drug regimens under fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.
お知らせ • Nov 09Elite Pharmaceuticals, Inc. to Report Q2, 2023 Results on Nov 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q2, 2023 results on Nov 14, 2022
お知らせ • Sep 08Elite Pharmaceuticals, Inc. Appoints Kirko Kirkov as Chief Commercial OfficerOn September 5, 2022, Elite Pharmaceuticals, Inc. entered into an employment agreement with Kirko Kirkov to serve as the Registrants’ Chief Commercial Officer effective September 6, 2022. Mr. Kirkov joins Elite as an accomplished and multi-faceted leader with more than twenty years of in-depth business development skills across international pharmaceutical organizations. Before joining the Registrant, Mr. Kirkov served as General Manager of Vertice Pharma, a specialty generics pharmaceutical company, from February 2020 to present. From April 2008 to February 2020, Mr. Kirkov was employed by Sandoz and served in positions of increasing responsibilities beginning with Country Head & Managing Director of Bulgaria from 2008 to 2011. From 2011 to 2013, Mr. Kirkov served as Sandoz’s Business Unit Head, Branded Prescription Generics in Russia, and most recently, from January 2013 to February 2020, served as Sandoz’s Executive Director, Commercial Operations. Mr. Kirkov brings with him a broad range of experience in the areas of business development, operationalization of commercial strategy, and implementation of retail and wholesale channel sales operations, having overseen sales portfolios consisting of 400+ product families, and 1500+ SKUs covering both generic and branded products. Mr. Kirkov has a Bachelor of Science in Mechanical Engineering /Engineering Management from the University of Ottawa, two Masters of Science degrees respectively in Naval Architecture and Ocean Systems Management from the Massachusetts Institute of Technology, a Masters of Science in Applied Positive Psychology and Coaching from the University of East London, and an MBA from the University of Durham. Mr. Kirkov joins Elite in a newly created position to oversee the sale and marketing of commercial products not under license under Elite’s label.
お知らせ • Aug 12Elite Pharmaceuticals, Inc. to Report Q1, 2023 Results on Aug 15, 2022Elite Pharmaceuticals, Inc. announced that they will report Q1, 2023 results on Aug 15, 2022
お知らせ • Jun 24Elite Pharmaceuticals, Inc. to Report Fiscal Year 2022 Results on Jun 29, 2022Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2022 results on Jun 29, 2022
お知らせ • May 12Elite Pharmaceuticals, Inc. Announces the Appointment of Robert Chen, CPA/MPA, as Chief Financial Officer, Effective May 16, 2022, Succeeding Marc BregmanElite Pharmaceuticals, Inc. announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer, effective May 16, 2022, succeeding Marc Bregman. Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and public, ranging from preclinical development to commercial operations. Mr. Chen brings with him extensive and diversified financial leadership background in the areas of financial reporting, including manufacturing, financial and cost accounting, SEC, GAAP and IFRS, as well as financial planning and analysis. Mr. Chen previously served in roles as CFO, Vice President of Finance, and Corporate Controller primarily in the life sciences sector. Mr. Chen most recently served as Vice President of Finance for KBP Biosciences, a clinical-stage biotech start-up. Mr. Chen also held financial positions with Bradley Pharmaceuticals, Novartis, Victory Commercial Management, Medimetriks Pharmaceuticals, and Taiho Oncology.
お知らせ • Apr 19+ 1 more updateMarc Bregman Notifies Elite Pharmaceuticals, Inc. of His Intent to Leave and Resign from His Position as Chief Financial Officer, Treasurer and SecretaryOn April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc. of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary to pursue another opportunity. Mr. Bregman's last day with the Company will be April 29, 2022.
お知らせ • Feb 10Elite Pharmaceuticals, Inc. to Report Q3, 2022 Results on Feb 14, 2022Elite Pharmaceuticals, Inc. announced that they will report Q3, 2022 results on Feb 14, 2022
お知らせ • Feb 11Elite Pharmaceuticals, Inc. to Report Q3, 2021 Results on Feb 16, 2021Elite Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Feb 16, 2021
お知らせ • Nov 12Elite Pharmaceuticals, Inc. to Report Q2, 2021 Results on Nov 16, 2020Elite Pharmaceuticals, Inc. announced that they will report Q2, 2021 results at 8:40 PM, GMT Standard Time on Nov 16, 2020
お知らせ • Aug 13Elite Pharmaceuticals, Inc. to Report Q1, 2021 Results on Aug 14, 2020Elite Pharmaceuticals, Inc. announced that they will report Q1, 2021 results at 8:40 PM, GMT Standard Time on Aug 14, 2020
